{"commentary":{"count":36,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":20,"youtube":8,"podcast":8},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03945773\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CaboPoint","nct_id":"NCT03945773","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cabopoint-nct03945773. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"CaboPoint","arms":[{"description":"Subjects who radiographically progressed after one prior line by CPI therapy with ipilimumab and nivolumab.","label":"Cohort A","type":"EXPERIMENTAL"},{"description":"Subjects who radiographically progressed after one prior line by CPI therapy combined with VEGF-targeted therapy.","label":"Cohort B","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-02-12","type":"ACTUAL"},"conditions":["Locally Advanced or Metastatic Renal Cell Carcinoma"],"enrollment":{"count":127,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Cabozantinib","type":"DRUG"}],"last_update":"2026-10-06","lead_sponsor":"Ipsen","official_title":"A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors.","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-05-11","type":"ACTUAL"},"primary_outcomes":[{"measure":"Cohort A: Objective Response Rate (ORR) Assessed by Independent Central Review","timeFrame":"Tumour assessments performed at Screening/Baseline (within 28 days prior start of study treatment) and every 12 weeks, up to approximately 40 months"}],"references":[{"citation":"Albiges L, Schmidinger M, Taguieva-Pioger N, Perol D, Grunwald V, Guemas E. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma. Future Oncol. 2022 Mar;18(8):915-926. doi: 10.2217/fon-2021-1006. Epub 2021 Dec 16.","pmid":"34911359","type":"DERIVED"}],"start_date":{"date":"2020-01-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors","url":"https://clinicaltrials.gov/study/NCT03945773"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cabopoint-nct03945773"}